A Phase 1 interventional study of MEDI1341 and Placebo in Parkinson's Disease, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-09.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48 healthy volunteers, aged 18 to 65 years. The study will include up to 6 planned cohorts; each cohort will comprise 8 participants.
Each participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled assessments over a period of 13 weeks.
The main aim of the study is to assess the safety and tolerability of single doses of MEDI1341 in healthy volunteers.
This is a randomized, double-blind, placebo-controlled study of single ascending intravenous doses of MEDI1341 in male and nonfertile female healthy volunteers, aged 18 to 65 years.
The study will include up to 6 planned cohorts; each cohort will comprise 8 participants. Within each cohort, 6 participants will be randomized to receive MEDI1341 and 2 will be randomized to receive placebo. A Safety Review Committee will review data from each cohort before progression to the next higher dose cohort occurs. On Day 1, each randomized participant will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and will undergo scheduled safety, pharmacokinetic, pharmacodynamic, and immunogenicity assessments. Additional study assessments will occur on Days 2, 4, 8, 15, 22, 29, 43, 57, and 92.
Exclusion Criteria:
Participants will receive a single intravenous (IV) infusion of placebo matched to MEDI1341 and will be followed up for 13 weeks.
Drug: Placebo
Participants will receive a single IV infusion of MEDI1341 Dose 1 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive a single IV infusion of MEDI1341 Dose 2 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive a single IV infusion of MEDI1341 Dose 3 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive a single IV infusion of MEDI1341 Dose 4 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive a single IV infusion of MEDI1341 Dose 5 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive a single IV infusion of MEDI1341 Dose 6 and will be followed up for 13 weeks.
Drug: MEDI1341
Participants will receive IV infusion of MEDI1341 doses as stated in the arms' description.
Also known as: TAK-341
Participants will receive IV infusion of placebo matched to MEDI1341.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 92 days after a single dose of study drug
Number of Participants With Abnormal Vital Signs, Physical and Neurological Examinations, and Body Weight Measurements Reported as TEAEs
Vital signs assessment included body temperature, respiration rate, pulse rate, and blood pressure. Participants with abnormal vital signs, physical and neurological examinations, and body weight measurements reported as TEAEs are reported.
Time frame: Day 1 through 92 days after a single dose of study drug
Change from Baseline in 12-Lead Electrocardiogram (ECG) Data in Paper and Digital Recordings (PR Interval, QRS Duration, QT Interval, QTcF Interval, and RR Interval)
Changes from baseline in 12-Lead ECG data in paper recordings (PR interval, QRS duration, QT interval, and QTcF interval) and digital recordings (PR interval, QRS duration, QT interval, QTcF interval, and RR interval) are reported.
Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
Change from Baseline in Heart Rate by 12-Lead ECG in Paper and Digital Recordings
Change from baseline in heart rate by 12-Lead ECG in paper and digital recordings are reported.
Time frame: 12-lead paper ECG: Baseline (Day -49) to Day 92; Digital ECG: Baseline (Day 1) to Day 92
Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs
Laboratory assessment included hematology, clinical chemistry, and urinalysis. Participants with abnormal laboratory parameters reported as TEAEs are reported.
Time frame: Day 1 through 92 days after a single dose of study drug
Number of Abnormal Findings for Ophthalmic Assessment (Ophthalmic Examination and Slit-lamp Examination) for Placebo and Cohorts 4 to 6 at Follow-up Visit
Number of abnormal findings for ophthalmic assessment (ophthalmic examination and slit-lamp examination) at follow-up visit (Day 57) are reported.
Time frame: Follow-up Visit (Day 57)
Intraocular Pressure at Screening for Placebo and Cohorts 4 to 6
Intraocular pressure at Screening (Day -49) is reported.
Time frame: Screening (Day -49)
Intraocular Pressure at Day 29 for Placebo and Cohorts 4 to 6
Intraocular pressure at Day 29 is reported.
Time frame: Day 29
Intraocular Pressure at Day 92 for Placebo and Cohorts 4 to 6
Intraocular pressure at Day 92 is reported.
Time frame: Day 92
Number of Participants With Injection Site Reactions
Participants who had injection site reactions (bleeding, bruising, erythema, swelling, or induration) on Day 1 are reported.
Time frame: Day 1
Visual Analogue Scale (VAS) Pain Score for Site Reaction Pain
The VAS (0 to 10 cm) was used to describe reaction site pain. The score 0 means 'no pain at all' and 10 score means 'worst pain imaginable'. The higher the VAS score, the greater the reaction site pain experienced.
Time frame: Day 1 (within 24 hours after end of infusion)
Number of Participants With Suicidal Ideation and Suicidal Behavior Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a scale capturing occurrence, severity, and frequency of suicide-related thoughts and behaviours, and has a binary response (yes/no). * Suicidal Ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. * Suicidal Behaviour: a "yes" answer to any of 5 suicidal behaviour questions: preparatory acts or behaviour, aborted attempt, interrupted attempt, actual attempt (non-fatal), completed suicide.
Time frame: Screening (Day -49) through 92 days after a single dose of study drug
Number of Participants With Montreal Cognitive Assessment (MoCA) Total Score at Screening (Day -1)
The MoCA is s standardized cognitive screening tool for mild cognitive impairment and dementia. The total score was used as outcome measure and this score ranges from 0-31, with higher scores representing better cognitive ability and scores below 26 were considered as cognitive dysfunction.
Time frame: Screening (Day -1)
Number of Participants With MoCA Total Score at Day 92
The MoCA is s standardized cognitive screening tool for mild cognitive impairment and dementia. The total score was used as outcome measure and this score ranges from 0-31, with higher scores representing better cognitive ability and scores below 26 were considered as cognitive dysfunction.
Time frame: Day 92
Maximum Observed Serum Concentration (Cmax) of MEDI1341
The Cmax of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Time to Maximum Serum Concentration (tmax) of MEDI1341
The tmax of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Area Under the Serum Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of MEDI1341
The AUC0-t of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of MEDI1341
The AUC0-∞ of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Terminal Half-life (t1/2λz) of MEDI1341
The t1/2λz of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Serum Clearance (CL) of MEDI1341
The CL of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Volume of Distribution at Steady State (Vss) of MEDI1341
The Vss of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Mean Residence Time (MRT) of MEDI1341
The MRT of MEDI1341 is reported.
Time frame: Day 1 (predose; 0 minute and 8 and 24 hours at the end of infusion), and Days 4, 8, 15, 22, 29, 43, 57, and 92
Percentage Change From Baseline in Plasma Concentrations of Total α-synuclein
Maximum change from baseline through Day 92 and change from baseline at Day 92 in plasma concentrations of total α-synuclein are reported.
Time frame: Baseline (Day 1 predose) through Day 92
Percentage Change From Baseline in Cerebrospinal Fluid Concentrations of Free α-synuclein
Change from baseline in cerebrospinal fluid concentrations of free α-synuclein is reported.
Time frame: Baseline (Day 1 predose) and Day 29
Percentage of Participants With Positive Antidrug Antibodies (ADAs) to MEDI1341 by Titer Levels at Day 92
Percentage of participants with positive ADAs to MEDI1341 by titer levels are reported.
Time frame: Day 92
Plan to share: Yes — Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca